Teva Pharmaceutical Reports Q2 Earnings with Growth in Innovative Medicines
Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter revenue of approximately $4.1 billion, a slight decline from the previous year due to lower sales from generic Revlimid being partially offset by growth in its innovative medicines portfolio. The company's CEO highlighted strong performance from AUSTEDO, UZEDY, and AJOVY, which together saw 43% revenue growth. Teva raised full-year guidance for these products as well as overall revenue expectations by $75 million at the midpoint. The innovative medicines portfolio is now a key driver of the company's strategy. Despite challenges in its generics segment due to lower launch activity and competition, Teva remains optimistic about biosimilars as an emerging growth area with 15 products currently on the market.
Tickers: $TEVA